Prestige International : FY2025.3 Q3 | Financial Results for the Q3, Fiscal Year Ending March 2025

Published January 29, 2025 at 7:16 a.m. UTC

Source: MarketScreener

Financial Results｜Q3

Fiscal Year Ending March 2025

April 1, 2024 - December 31, 2024

January 29, 2024

Securities Code 4290

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Executive Summary

Achieve solid growth by

expanding core businesses

Performance was in line with full-year forecast, driven by growth in core businesses.
Excluding vaccine-related operations, YoY change in existing business.

Sales: +12.3%｜Operating Profit: +15.2%

*P28: Reference｜Impact of Vaccine-Related Operations on Financial Results

Repurchase of shares

of common stock

Resolved at the Board of Directors meeting held on November 19, 2024
Repurchase commenced in the Q3 of FY ending March 2025.

*P19: Reference｜Shareholder Returns

Progress in the establishment of the new center

Finalization of the basic design for new office Akita BPO Katagami Campus (provisional name)

(Plant to open in August, 2026)

▍Financial Results Summary for Q3 FY2025.3

▍Financial Results Summary for Q3 FY2025.3 by Segment

▍Shareholder Returns

▍Sustainability

▍Appendix

▍Financial Results Summary for Q3 FY2025.3

Summary of Consolidated Results｜FY2025.3｜Q3

(million yen)

FY2024.3｜Q3

FY2025.3｜Q3

Amounts are rounded down to the nearest whole unit.

YoY	Full-Year	Progress(%)
(%)	Forecast	vs. Full-Year Forecast

Sales	43,744	47,600	+3,855	63,000	75.6%
(+8.8%)


Operating profit	5,854	6,000	+145	8,000	75.0%
(+2.5%)


Ordinary profit	6,226	6,413	+186	8,500	75.5%
(+3.0%)


Profit attributable to	3,854	3,665	-189	5,300	69.2%
owners of parent	(-4.9%)


◼ Sales	All businesses except for the Customer Business are growing steadily due to the expansion of
	existing businesses, the revision of consignment fees, and the launch of new services, etc., and

are in line with the full-year forecast.

◼	Operating Profit	Due to the completion of the relatively profitable vaccine-related operations, the decrease in profit
		was absorbed by the increase in sales, resulting in an increase in profit.
◼	Profit attributable to	Due to the loss of tax benefits resulting from the liquidation of a subsidiary that occurred in the
	owners of parent	previous fiscal year, the amount of income taxes-deferred increased, resulting in a decrease in
		profit.

Consolidated P&L Statement｜FY2025.3｜Q3

(million yen)			Amounts are rounded down to the nearest whole unit.

	FY2024.3｜Q3	FY2025.3｜Q3	Change	YoY(%)

Sales	43,744	47,600	+3,855	+8.8%

Cost of sales	33,577	37,101	+3,523	+10.5%

Gross profit	10,167	10,499	+332	+3.3%

Gross profit margin	23.2%	22.1%	(-1.1pt)	―

SG&A	4,312	4,499	+187	+4.3%

Operating profit	5,854	6,000	+145	+2.5%

Operating profit margin	13.4%	12.6%	(-0.8pt)	―

Ordinary Profit	6,226	6,413	+186	+3.0%

Ordinary profit margin	14.2%	13.5%	(-0.7pt)	―

Profit attributable to	3,854	3,665	-189	-4.9%
owners of parent

Consolidated Balance Sheet｜As of End of December, 2024

(million yen)			Amounts are rounded down to the nearest whole unit.

	End of March	End of December	Change	Change(%)
	2024	2024


Current assets	40,740	41,397	+656	+1.6%

Non-current assets	27,096	29,396	+2,300	+8.5%

Total assets	67,836	70,794	+2,957	+4.4%

Current liabilities	17,778	18,561	+782	+4.4%

Non-current liabilities	2,832	3,098	+265	+9.4%

Total liabilities	20,611	21,659	+1,047	+5.1%

Shareholders' equity	40,603	41,800	+1,196	+2.9%

Accumulated other	3,418	3,909	+491	+14.4%
comprehensive income


Non-controlling	3,203	3,424	+221	+6.9%
interests, etc.


Total net worth	47,224	49,134	+1,909	+4.0%

Total liabilities and	67,836	70,794	+2,957	+4.4%
equity

Quarterly Sales

(million yen)

	Q1			Q2		Q3			Q4														63,000



																							(forecast)
60,000																			58,738


																		54,562
50,000																46,744				14,993		47,600


																		14,110
40,000													37,196	42,377	40,617	12,483					16,830


												10,672


														33,119		10,568				14,981
																	14,272
													29,477		9,816
30,000										27,328
								24,619	8,684				11,967
				23,385	24,225					11,016
				22,223	6,936	7,596		9,478	10,309					14,845	15,721

										6,570
				6,281	6,133				8,488
20,000		6,010							13,568
						7,674
											6,920
																11,599
				6,010	5,716		6,462				10,687	10,266
				5,782			8,079	9,271

10,000										6,816	7,238
	5,838	6,449	5,422	6,050												15,048
											12,611	13,917
												10,001	9,473	10,693
														7,866	8,630
							5,926		5,536	6,654	6,967
				5,254	5,007
0

FY12.3	FY13.3	FY14.3	FY15.3	FY16.3	FY17.3	FY18.3	FY19.3	FY20.3	FY21.3	FY22.3	FY23.3	FY24.3	FY25.3

Due to rounding down fractions, some values may not equal the sum of the separate figures.

Quarterly Operating Profit

(million yen)
		Q1			Q2		Q3		Q4		OPM(full-year)						14.6%	14.4%

12,000
																						13.5%	12.7%
								12.6%				12.8%	12.8%	12.6%		12.9%
																			(forecast)
										12.2%
10,000								12.0%				11.7%

11.2%

						9.8%												7,840	7,921	8,000
8,000																	(forecast)
															6,842
																			1,799			2,066
																								6,000
6,000
												4,687	4,959	5,233	1,918



																		2,201
														4,230						1,997	2,270
																1,374
													3,768		1,179
4,000										3,345		1,491		1,860
			2,621			2,809	2,952	1,064	1,368	1,362	1,247

			2,380			966				1,953	1,967
					762			1,193			2,000
						746		1,051			1,579
			891				926
2,000	720
		737	858		1,128	1,314
			782			1,023
			619	468				877	877
			672	790	745				1,886	1,889
			605	651		933	978	1,289	1,296	1,484	1,729
			609	661	775	899
0	504	540

FY12.3 FY13.3 FY14.3 FY15.3 FY16.3 FY17.3 FY18.3 FY19.3 FY20.3 FY21.3 FY22.3 FY23.3 FY24.3 FY25.3

15.0%

12.0%

9.0%

6.0%

3.0%

0.0%

Due to rounding down fractions, some values may not equal the sum of the separate figures.

▍Financial Results Summary for Q3 FY2025.3 by Segment